1 min read
China remains one of the most attractive pharmaceutical markets globally, but navigating China's pharmaceutical regulations requires strategic planning, Regulatory expertise, and strong compliance management. With evolving NMPA requirements, electronic submission standards, and accelerated review pathways, pharmaceutical companies must prepare carefully before entering the Chinese market.
Here are 8 essential steps for successful pharmaceutical registration and market entry in China.
Step 1: Determine Product Classification
Identify whether the product qualifies as:
- Innovative drug
- Generic drug/Biosimilar
- Medical urgent need products
- Rare disease therapy/paediatric products/life-threatening therapy
Product classification determines the Regulatory pathway, data requirements, and submission timelines.
Step 2: Define a China Regulatory Strategy
Develop a strategy that considers:
- Clinical studies development/bridging/waiver
- Align the strategy/requirements with Health Authorities by Communication
- NMPA submission strategy & timelines
- eCTD readiness
- Lifecycle management planning
Step 3: Appoint Local Representation
Foreign pharmaceutical companies typically require local Regulatory support or authorized representation to manage communications and submissions with the NMPA.
Step 4: Conduct a Regulatory Gap Assessment
Evaluate:
- Dossier readiness
- China CTD requirements
- Labelling/Label compliance
- GMP alignment
- Pharmacovigilance systems
- Technical documentation quality
Step 5: Prepare eCTD-Compliant Documentation
China’s electronic submission requirements continue evolving. Ensure:
- China-specific dossier formatting
- Accurate technical validation
- High-quality translations
- Proper lifecycle sequence management
Step 6: Submit Registration Application
Prepare and submit:
- Administrative documents
- Quality and CMC data
- Nonclinical documentation
- Clinical data
- Pharmacovigilance & Risk management plans
Step 7: Prepare for NMPA Review & Inspections
Companies should prepare for:
- QC test
- Technical deficiency responses
- GMP inspections (risk-based)
- Manufacturing site audits
- Data integrity assessments
Step 8: Maintain Post-Approval Compliance
Ongoing compliance obligations include:
- Pharmacovigilance reporting
- Variation management
- Periodic safety updates
- GMP compliance monitoring
- Lifecycle management activities
Conclusion
China offers substantial opportunities for pharmaceutical and biotechnology companies, but success requires proactive Regulatory planning, strong compliance systems, and localized expertise.
Freyr supports pharmaceutical companies with China product registration, NMPA compliance, eCTD submissions, Regulatory affairs consulting, pharmacovigilance, and lifecycle management services. Talk to our expert today.
